1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   Response -  Analytic Code
   
   
3. Who will be able to view these files?
   Response - Anyone
   


4. For what types of analyses will this data be available?
   Response - Any purpose.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [prachifcb3@gmail.com].
   


6. For how long will this data be available start date provided 01-07-2023 and end date provided 08-01-2027?
   Response - Immediately following publication. No end date.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - nil

1.Pre Procedural pain will be assessed during rest as well as movement of 15° passive elevation of affected limb and recorded on numeric pain rating scale (NRS) 0=no pain,10=worst imaginable pain.

2. At 30mins after administering the block, pain will be measured by NRS at rest and on passive limb elevation of 15°. (Primary objective)

If the patient reports a NRS score ≥4 during 15° passive elevation of affected limb, intravenous fentanyl 0.5 μg/kg body weight will be given and 15° passive elevation of affected limb will be re-attempted after 5 minutes. If still NRS score is ≥4 then Inj. fentanyl 0.5 μg/kg body weight will be repeated every 5 minutes up to maximum of 3 doses.

3. Patient will be made to sit up for positioning for subarachnoid block after NRS score on 15 degree passive limb elevation is < 4 or after 3 doses of fentanyl have been given and NRS pain score  will be noted on sitting up the patient for positioning for subarachnoid block.

4. Total amount of supplemental fentanyl if required for decreasing NRS pain score on 15° passive elevation of affected limb at 30 minutes after administration of block will be noted.

5. The ease of spinal positioning (EOSP) will be assessed on the scale of 0–3 (0 = unable to position, 1 = patient had abnormal posturing due to pain and required support for positioning, 2 = mild discomfort but does not require support for positioning, 3 = optimal condition where the patient was able to position himself without pain).

6. Quality of patient position for subarachnoid block as assessed by anaesthesiologist performing subarachnoid block will be evaluated as

0=Unsatisfactory, 1=Satisfactory, 2=Good or 3=Optimal.

Subarachnoid  block will be performed using a median or paramedian approach at the L3-L4 or L4-L5 interspace using spinal needle using 3 ml of 0.5% bupivacaine + fentanyl 10 µg.

7. Heart rate, non invasive blood pressure (systolic ,diastolic, Mean), respiratory rate and SpO₂ will be recorded ; a) at rest at 5, 10 ,20, 30 minutes after performing the block procedure, b) on  15 degree passive limb elevation at 30 minutes after performing the block and c) on positioning patient ( in sitting up position ) for subarachnoid block.

 Intraoperative monitoring of heart rate, noninvasive blood pressure (systolic, diastolic and mean) and SpO2 will be done.

8. Complications such as hypotension (a decrease of mean blood pressure >20% from preanaesthetic baseline values), bradycardia (HR <40 beats/min), hypoventilation (breathing rate <8 breaths/min), nausea and vomiting and signs of LA toxicity will be noted and treated. After surgery, all patients will be transferred to post anesthesia care unit, and hemodynamic parameters will be monitored. All patients will receive paracetamol 1gm intraveously 8 hourly.

9.Patient satisfaction score will be noted after positioning patient in sitting up position for subarachnoid block:

Score 1- Good (Will definitely accept the block again in future if required).

Score 2- Poor (will never accept the block again in future if required).